Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05053503 · ClinicalTrials.gov registry record · NA
Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder
A NA study, sponsored by Spark Biomedical.
- Completed
- Registry status
- NA
- Development phase
- 108
- Enrollment target
NCT05053503 is a NA study that has completed, run by Spark Biomedical. The registered enrollment target is 108 participants.
The verdict
NCT05053503, a NA study, has completed, sponsored by Spark Biomedical.
- COMPLETED
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
Study Summary
The primary objective of this trial is to determine whether tAN can improve relapse prevention beyond that seen with extended-release injectable naltrexone during Phase II.
Interventions
- DRUG Lofexidine
- DEVICE Sparrow Ascent Therapy System
- DRUG Extended-release injectable naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2025-04-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05053503
The ClinicalTrials.gov registry entry for NCT05053503 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spark Biomedical, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lofexidine is the first listed.
NCT05053503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05053503 about?
NCT05053503 is a clinical study titled "Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder". The primary objective of this trial is to determine whether tAN can improve relapse prevention beyond that seen with extended-release injectable naltrexone during Phase II.
What is the current status of trial NCT05053503?
This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2022-05-27. Estimated completion is 2025-04-04.
What interventions are being tested in trial NCT05053503?
The interventions under investigation include: Lofexidine (DRUG), Sparrow Ascent Therapy System (DEVICE), Extended-release injectable naltrexone (DRUG).
Who is sponsoring clinical trial NCT05053503?
This trial is sponsored by Spark Biomedical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.